Standout Papers

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma 2023 2026 202481
  1. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma (2023)
    Toni K. Choueiri, Thomas Powles et al. New England Journal of Medicine

Citation Impact

1 by Nobel laureates 3 from Science/Nature 61 standout
Sub-graph 1 of 23

Citing Papers

Targeting immunogenic cell stress and death for cancer therapy
2024 Standout
Renal cell carcinoma
2024 Standout
1 intermediate paper

Works of Fong Wang being referenced

Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.
2024
A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk.
2020
and 2 more

Author Peers

Author PRM Oncology RNMI Molecular Biology Cancer Research Last Decade Papers Cites
Fong Wang 660 221 178 263 238 26 1.1k
K. Bloch 15 2 4 25 9 286
Stephen E. Wood 2 3 14 639
Emily Rose 1 18 385
S.H. Muhle 15 7 24 23 407
Mohammad Gholami 1 2 1 36 274

All Works

Loading papers...

Rankless by CCL
2026